Immunotech Biopharm Ltd’s Rights Issue Oversubscribed, Raising HK$257.29 Million
Immunotech Biopharm Ltd has successfully completed its rights issue, raising approximately HK$257.29 million, with net proceeds estimated at HK$251.88 million. The oversubscription reflects strong investor confidence, which may enhance the company's financial position and operational capabilities. Immunotech Biopharm Ltd operates in the biopharmaceutical industry, focusing on innovative healthcare solutions, and has a current market cap of HK$2.03 billion.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Immunotech Biopharm Ltd ( (HK:6978) ) has provided an announcement.
Immunotech Biopharm Ltd announced the successful completion of its rights issue, which was significantly oversubscribed. The company raised approximately HK$257.29 million in gross proceeds, with net proceeds estimated at HK$251.88 million, which will be used according to their planned allocation. The oversubscription indicates strong investor confidence and could enhance the company’s financial position and operational capabilities.
More about Immunotech Biopharm Ltd
Immunotech Biopharm Ltd is a company incorporated in the Cayman Islands, operating in the biopharmaceutical industry. It focuses on developing and manufacturing innovative biopharmaceutical products, with a market focus on advancing healthcare solutions.
Average Trading Volume: 1,550,617
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.03B
